Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2020 Jun 15.

Published in final edited form as: Clin Cancer Res. 2019 Sep 16;25(24):7396–7404. doi: 10.1158/1078-0432.CCR-19-0740

Figure 3. — A. At a specificity cut-off of 91% by the model, the 5-marker panel was able to detect 43% stage I, 64% stage II, 77% stage III, and 92% stage IV disease. The marker panel detected 74% of esophageal cancer overall, 74% of esophageal adenocarcinoma, and 78% of esophageal squamous cell carcinoma. Confidence intervals are shown. B. Overall discrimination of esophageal cancer by methylated DNA marker panel assayed from plasma: areas under the receiver operating characteristic curves for best-fit and cross-validation analyses (and 95% confidence intervals) are shown.

AUC, area under the receiver operating characteristics curve.

Figure 3. — A. At a specificity cut-off of 91% by the model, the 5-marker panel was able to detect 43% stage I, 64% stage II, 77% stage III, and 92% stage IV disease. The marker panel detected 74% of esophageal cancer overall, 74% of esophageal adenocarcinoma, and 78% of esophageal squamous cell carcinoma. Confidence intervals are shown. B. Overall discrimination of esophageal cancer by methylated DNA marker panel assayed from plasma: areas under the receiver operating characteristic curves for best-fit and cross-validation analyses (and 95% confidence intervals) are shown.

AUC, area under the receiver operating characteristics curve.